Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hyperglycemia

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era.

Current diabetes reviews·2023

Same author

Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines.

Clinical medicine insights. Endocrinology and diabetes·2022

Same author

Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2020

Same author

Persistent Elevation of Parathormone Levels after Surgery for Primary Hyperparathyroidism.

Indian journal of endocrinology and metabolism·2020

Same author

Expert Group Recommendations on Detection and Management of Hypoglycemia in Routine Clinical Practice in Insulin Treated Patients with Diabetes.

The Journal of the Association of Physicians of India·2019

Same author

Primary hyperparathyroidism: A changing scenario in India.

Indian journal of endocrinology and metabolism·2016

Search research articles

Related Experiment Video

Updated: May 8, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glycemic variability: Clinical implications.

Surabhi Venkata Satya Krishna¹, Sunil K Kota, Kirtikumar D Modi

¹Department of Endocrinology, Medwin Hospital, Hyderabad, Andhra Pradesh, India.

Indian Journal of Endocrinology and Metabolism

|August 21, 2013

Summary

This summary is machine-generated.

Glycemic variability (GV) is linked to cardiovascular risk in diabetes. Minimizing GV, alongside other glycemic measures, may help prevent cardiovascular events in Type 2 diabetes patients.

Keywords:

Diabetes mellitus glycemic variability incretins oxidative stress

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Related Experiment Videos

Last Updated: May 8, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Area of Science:

Endocrinology
Metabolic Diseases
Cardiovascular Research

Background:

Prospective trials confirm glycemic control prevents microvascular diabetic complications.
The Diabetes Control and Complications Trial (DCCT) linked variable glycated hemoglobin (HbA1C) to increased microvascular issues.
The direct link between glycemic variability and macrovascular complications remains under investigation.

Purpose of the Study:

To explore the role of glycemic variability (GV) in cardiovascular risk among diabetic patients.
To highlight GV as a crucial factor in diabetes management, alongside fasting blood sugar, postprandial blood sugar, HbA1C, and quality of life (the glycemic pentad).
To discuss the mechanisms, clinical implications, and control strategies for GV.

Main Methods:

Review of existing literature on glycemic control, variability, and cardiovascular events in diabetes.
Analysis of the proposed 'glycemic pentad' for comprehensive diabetes management.
Discussion of modern therapeutic approaches addressing GV.

Main Results:

Glycemic variability (GV), encompassing postprandial spikes and hypoglycemia, is implicated in increased cardiovascular events in Type 2 diabetes.
Minimizing GV is proposed as a strategy to prevent future cardiovascular events.
Modern diabetes management strategies effectively address GV.

Conclusions:

Glycemic variability is a significant factor contributing to cardiovascular risk in diabetic patients.
Comprehensive diabetes management should consider GV alongside other glycemic parameters.
Current therapeutic advancements offer effective means to control GV and potentially mitigate cardiovascular risks.